Semax for Stroke Recovery: Neuroprotection Evidence
Semax
30-50%
Semax reduced cerebral infarct volume by 30-50% in middle cerebral artery occlusion models when administered within the therapeutic window.
Romanova et al., Bulletin of Experimental Biology and Medicine, 2006
Romanova et al., Bulletin of Experimental Biology and Medicine, 2006
View as imageWhen blood supply to the brain is interrupted during a stroke, neurons begin dying within minutes. The race to limit damage depends on restoring blood flow (thrombolysis) and protecting the surviving neurons in the ischemic penumbra, the border zone around the dead core where cells are stressed but not yet lost. Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic analog of the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro stabilizing extension, has been studied as a neuroprotective agent in this context for over two decades. For the broader picture of semax research, see the article on how semax upregulates BDNF, the pillar for this cluster.
Key Takeaways
- Semax reduced infarct volume by 30-50% in rat models of middle cerebral artery occlusion (MCAO) and prevented post-ischemic memory deficits[1]
- Semax upregulated BDNF and TrkB receptor expression in the hippocampus, providing a neurotrophic mechanism for neuronal survival after ischemia[2]
- At the genomic level, semax suppressed inflammatory gene expression and activated neurotransmission-related genes within 24 hours of ischemic injury[3]
- Proteomic analysis confirmed semax altered protein expression patterns in ischemic brain tissue toward neuroprotection[4]
- Russian clinical studies report improved functional recovery and motor performance in stroke patients receiving semax, but these trials lack the rigor expected by Western regulatory standards
- Semax has no FDA approval; all clinical evidence comes from Russian institutions
What Semax Is
Semax is derived from the adrenocorticotropic hormone (ACTH) fragment consisting of amino acids 4-7 (Met-Glu-His-Phe). The tripeptide Pro-Gly-Pro was added to the C-terminus to slow enzymatic degradation and extend the peptide's biological half-life. This makes semax a seven-amino-acid synthetic melanocortin analog with no hormonal activity at the adrenal cortex; it does not stimulate cortisol production.
The peptide is administered intranasally at doses ranging from 200 to 6,000 mcg per day in clinical settings. It was approved in Russia in 2011 for the treatment of ischemic stroke, dyscirculatory encephalopathy, optic nerve atrophy, and cognitive disorders. It has no approval outside of Russia.
Animal Evidence: Reducing Infarct Volume
The MCAO model
The middle cerebral artery occlusion (MCAO) model is the standard experimental paradigm for ischemic stroke in rodents. Blood flow to a large portion of one hemisphere is blocked temporarily, creating a region of dead tissue (the infarct core) surrounded by the ischemic penumbra.
Romanova et al. (2006) tested semax in this model and found it reduced cerebral infarct volume by 30-50% when administered during the acute phase.[1] Beyond structural protection, semax also prevented the amnesia and learning deficits that typically follow experimental cerebral ischemia. Animals treated with semax performed better on memory tasks than untreated ischemic controls, indicating functional as well as anatomical neuroprotection.
The BDNF pathway
The mechanism behind this protection centers on brain-derived neurotrophic factor (BDNF), the brain's primary survival signal for neurons. Dolotov et al. (2006) showed that semax upregulated BDNF mRNA and its high-affinity receptor TrkB in the rat hippocampus.[2] Earlier work by the same group (Dolotov et al., 2003) had established that semax stimulates BDNF expression across multiple brain regions, not just the hippocampus.[5]
BDNF promotes neuronal survival through multiple pathways: it inhibits apoptosis (programmed cell death), supports synaptic plasticity, stimulates neurite outgrowth, and enhances the differentiation of neural progenitor cells. In the context of stroke, elevating BDNF in the penumbral zone could tip the balance from cell death toward survival for neurons that are injured but not yet lost.
Dolotov et al. (2006) also demonstrated that semax binds specifically to sites in brain tissue and increases BDNF protein levels, not just mRNA, confirming that the transcriptional effect translates into actual protein production.[6]
Shadrina et al. (2010) mapped the time course, comparing NGF and BDNF gene expression dynamics in hippocampus, frontal cortex, and cerebellum after semax administration. The temporal patterns differed across brain regions, suggesting region-specific neurotrophic responses rather than a blanket upregulation.[7]
Genomic and Proteomic Evidence
Gene expression changes after ischemia
Medvedeva et al. (2017) used genome-wide transcriptional analysis to examine how semax affects gene expression in the ischemic rat brain.[3] The results revealed a two-phase pattern:
In the first hours after ischemia, semax predominantly suppressed genes related to inflammatory processes. Inflammation in the ischemic brain is initially protective (clearing dead cells) but quickly becomes destructive, expanding damage beyond the original infarct zone. Reducing this inflammatory cascade is a recognized target for neuroprotection.
By 24 hours, semax had activated genes related to the immune and vascular systems, as well as neurotransmission. This later phase appears to shift the brain's response from acute damage control toward repair and recovery.
The scope of genomic changes was broad. Semax affected hundreds of genes simultaneously, consistent with its action through melanocortin receptor signaling and downstream transcription factor activation rather than a single molecular target.
Protein-level confirmation
Sudarkina et al. (2021) extended the evidence from gene expression to actual protein changes using proteomic analysis of brain tissue from rats subjected to cerebral ischemia-reperfusion.[4] The protein expression profile in semax-treated ischemic brains shifted toward neuroprotective patterns, confirming that the transcriptional changes identified by Medvedeva et al. translate into functional protein differences.
This multi-level evidence (gene expression changes leading to altered protein profiles leading to reduced infarct volume and preserved cognition) builds a mechanistic case that is stronger than any single line of evidence alone.
Beyond Stroke: Broader Neuroprotection
Semax's neuroprotective effects extend beyond ischemia models.
Levitskaya et al. (2004) showed semax protected dopaminergic neurons against MPTP-induced damage, a model for Parkinson's disease.[8] Eremin et al. (2005) demonstrated that semax activates both dopaminergic and serotonergic brain systems, suggesting a broader neuromodulatory profile that extends beyond pure neuroprotection.[9]
Radchenko et al. (2025) tested semax and a derivative in transgenic Alzheimer's disease mice and found improved behavioral performance and reduced amyloidosis, extending the neuroprotective evidence to neurodegenerative contexts.[10]
Liu et al. (2025) discovered an unexpected mechanism: semax targets the mu-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery, revealing a pathway entirely separate from BDNF that may contribute to its neuroprotective effects.[11]
Inozemtseva et al. (2024) added another dimension, demonstrating that semax produces antidepressant-like and antistress effects in animal models.[12] This is relevant because post-stroke depression affects approximately one-third of survivors and is independently associated with worse functional outcomes. A neuroprotective agent that also addresses the neuropsychiatric consequences of stroke would have particular clinical value, though this remains speculative until tested in stroke patients.
These findings position semax alongside other neuroprotective peptides like cerebrolysin, which is also used clinically for stroke recovery, and NAP peptide (davunetide), a neuroprotective peptide that advanced further in Western clinical development.
Clinical Evidence in Stroke Patients
Russian clinical studies have tested semax in ischemic stroke patients. The most cited study examined 30 patients treated with semax (added to conventional therapy) in the acute period of hemispheric ischemic stroke, compared to 80 control patients receiving standard care alone (PubMed: 11517472). Semax accelerated the recovery of neurological functions, particularly motor function, compared to conventional therapy alone.
A second study (PubMed: 29798983) evaluated semax at 6,000 mcg/day administered in two 10-day courses separated by 20-day intervals in 110 stroke patients. The treatment increased plasma BDNF levels, which remained elevated throughout the study period. Early rehabilitation combined with semax improved functional recovery and motor performance beyond what rehabilitation alone achieved.
A third study (PubMed: 10358912) investigated mechanisms of semax's neuroprotective effect during the acute period of ischemic stroke and reported neurological improvement.
Limitations of the clinical data
These clinical studies share critical limitations:
Sample sizes are small. The largest study included 110 patients, which is insufficient to detect modest but clinically meaningful effects with adequate statistical power.
Study designs vary in rigor. Not all studies were randomized or blinded. Control groups sometimes differed in composition. Outcome assessments may not have been performed by blinded evaluators.
All evidence comes from Russian institutions. No international replication has been published. The absence of multicenter, multinational trials means the findings have not been tested across different clinical practices, patient populations, or assessment methodologies.
Publication is primarily in Russian-language journals. This limits independent peer review by the broader neuroscience and stroke research communities.
No Western regulatory submission has been attempted. The level of evidence required for FDA or EMA approval (large, randomized, double-blind, placebo-controlled, multicenter trials with pre-specified endpoints) does not exist for semax.
These limitations do not mean semax is ineffective for stroke recovery. They mean the question has not been answered to the standard of evidence required to draw reliable clinical conclusions.
How Semax Compares to Other Neuroprotective Peptides
The neuroprotective peptide field has struggled to translate preclinical promise into clinical success. Hundreds of neuroprotective agents have reduced infarct volume in rodent stroke models, and nearly all have failed in human trials. This "translational gap" is the central challenge for the entire field, and it applies to semax.
Cerebrolysin, a mixture of neurotrophic peptides derived from pig brain, has more extensive clinical trial data, including multicenter trials, but its efficacy remains debated. The broader landscape of neurotrophic peptides shows that BDNF upregulation is a common mechanism across multiple neuroprotective candidates.
What distinguishes semax is its well-characterized mechanism at multiple levels (gene expression, protein changes, neurotrophic signaling, functional outcomes in animals) and its long clinical use in Russia. What it lacks is the quality of clinical evidence that would establish it as a proven stroke treatment internationally.
Delivery Route and Brain Access
Semax is delivered intranasally, which is not incidental to its neuroprotective action. The nasal mucosa provides a route to the central nervous system that partially bypasses the blood-brain barrier, delivering peptide to the brain more efficiently than systemic injection would for a molecule of this size. The olfactory and trigeminal nerve pathways connecting the nasal cavity to the brain enable direct transport of peptide molecules to frontal cortex and brainstem regions. The nasal delivery pathway is described in the sibling article.
For stroke neuroprotection specifically, the intranasal route has a practical advantage: it does not require intravenous access, which matters in pre-hospital and emergency settings where rapid administration could improve outcomes. Whether intranasal semax reaches the ischemic penumbra at sufficient concentrations to provide neuroprotection in humans, given the disrupted vasculature of stroke, has not been directly measured.
Unanswered Questions
Therapeutic window. The MCAO studies administered semax shortly after ischemia onset. In clinical practice, stroke patients often arrive at the hospital hours after symptom onset. Whether semax provides benefit when started 6, 12, or 24 hours post-stroke has not been systematically tested.
Optimal dose and duration. Russian clinical protocols use doses from 200 to 6,000 mcg/day with varying treatment durations. No dose-finding study of the design standard for modern drug development has been conducted.
Interaction with thrombolysis and thrombectomy. Modern stroke treatment centers on restoring blood flow through tissue plasminogen activator (tPA) or mechanical thrombectomy. Whether semax provides additive benefit when combined with these standard treatments is unknown.
Long-term outcomes. The clinical studies measured outcomes over weeks to months. Whether semax-treated stroke patients have better functional status at one year or five years has not been studied.
The Bottom Line
Semax demonstrates neuroprotective effects in ischemic stroke through a multi-level evidence base: BDNF upregulation, inflammatory gene suppression, neuroprotective protein expression shifts, and reduced infarct volume in animal models. Russian clinical studies report improved functional recovery in stroke patients, but these trials are small, not consistently randomized or blinded, and have not been replicated internationally. The mechanistic case is compelling. The clinical case remains incomplete by the standards required for international regulatory approval.